Regulus Therapeutics to host educational webinar about microRNA biology

Dec 10 2009

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.

The webinar, scheduled for 3:00 p.m. EST on Monday, December 14, 2009, will feature two leading researchers in the field of microRNA biology:

• Tom Tuschl, Ph.D., Professor at the Rockefeller University heading the Laboratory of RNA Molecular Biology and a Howard Hughes Medical Institute investigator, will discuss advances in microRNA discovery and highlight recent scientific advances from the Tuschl laboratory; and
• Markus Stoffel, MD, Ph.D., Professor at the Swiss Federal Institute of Technology, Institute of Molecular Systems Biology will discuss microRNA therapeutic strategies and highlight recent scientific advances from the Stoffel laboratory.

The discussion will be moderated by Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus Therapeutics Inc, a company leading the development of a novel class of high impact medicines that target microRNA.

“The body of knowledge about microRNA is growing exponentially, and there have been several significant advances in the field over the last twelve months,” said Dr. Xanthopoulos. “This educational webinar, geared toward scientists, members of the media, and the investment community, will serve as an update on the latest discoveries, as well as provide insight into how they might be translated into the medicines of tomorrow.”